Celcuity Q2 Loss Widens to $78.9M on Launch Costs; $50M Pfizer Milestone Accrued
CELC sits 96% above its 52-week low of $44.42.
Summary
Celcuity reported a wider Q2 net loss of $78.9 million on commercialization spending, recognized a $50 million Pfizer milestone, and disclosed $754 million in cash runway into 2029.
Key Events · Earnings and Guidance · CELC
-
Q2 Net Loss Widens to $78.9M
Net loss for Q2 2026 was $78.9 million, up from $45.3 million in Q2 2025, driven by a $27.4 million increase in selling, general and administrative expenses to $35.0 million as the company scaled commercial operations for REVTORPYK.
-
$50M Pfizer Milestone Accrued
Following FDA approval on July 14, 2026, Celcuity recognized a $50.0 million accrued license milestone and corresponding intangible asset as of June 30, 2026, payable to Pfizer within 60 days.
-
$11.5M Debt Extinguishment Loss
The company recorded an $11.5 million non-cash loss on debt extinguishment after using $137.4 million of convertible note proceeds to voluntarily prepay its Amended & Restated Loan Agreement on June 8, 2026.
-
Cash Runway into 2029
Cash, cash equivalents and short-term investments totaled $754.0 million as of June 30, 2026. Management believes this is sufficient to fund planned operations at least into 2029.
Analysis · CELC · Industrial Applications And Services
Celcuity's second-quarter loss widened to $78.9 million from $45.3 million a year earlier, driven by a $27.4 million surge in selling, general and administrative expenses as the company built out its commercial infrastructure for REVTORPYK. The quarter also included an $11.5 million non-cash loss on debt extinguishment from paying off its secured loan. The company recognized a $50 million accrued license milestone to Pfizer following FDA approval, and ended the quarter with $754 million in cash and investments, which management says funds operations into 2029.
At the time of this filing, CELC was trading at $87.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $44.42 to $151.02. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.